Ion Beam Applications SA is excited to share its latest proton therapy insights during the Annual Congress and exhibition of the European Society for Radiotherapy & Oncology (ESTRO) being held in Copenhagen (Denmark) from 6-10 May, 2022. Together with its customers, IBA is leading proton therapy by developing treatment and dosimetry solutions for optimal patient care. Firstly, the Proteus® technology is designed by users for users with four objectives in mind: Clinical Confidence: Designed for clinical excellence and the most advanced patient care, Proteus® is a versatile proton therapy system which allows oncology centers to treat a broad range of tumors safely and effectively.

Superior patient workflow: Proteus® is inspired by everyday clinical practice. The Proteus® design enhances the patient experience by fostering a relaxing environment whilst making the medical staff's daily practice safe and easy. Shaping the future of proton therapy: IBA's product roadmap aims at shaping the future of proton therapy, intending to augment the potential of proton therapy in terms of therapeutic gain, ease of use, and/or benefit-cost ratio.

IBA continues its commitment to developing clinically relevant innovations designed to improve patient treatment in partnership with its users. Business excellence: With 35 years' experience, IBA is the world leader in its field. It boasts the largest number of operating sites, rooms and field teams in the industry, as well as robust and updated processes.

Additionally, IBA is proud to demonstrate its Campus platform for the first time at ESTRO. First launched in October 2021 and representing the largest community of proton therapy experts, Campus has been built in collaboration with IBA's clinical and industry partners. It is a unique place where the whole proton therapy community can discuss, collaborate, and share insights with each other, as well as receive training.